 Effects recombinant human human hematopoietic progenitor precursor cells vivo DNA-synthesis rates concentrations bone marrow BM peripheral blood PB progenitor cells patients recombinant human part clinical phase I/II study Recombinant doses subcutaneous bolus injection days patients solid tumors hematopoietic function patients bone marrow failure myelodysplastic syndromes treatment percentage BM erythroid BFU-E multilineage CFU-GEMM progenitors patients preserved hematopoietic function DNA-synthesis rates early late granulocyte macrophage progenitor cells CFU-GM day CFU-GM day increase BM cellularity myeloid ratio concentration marrow progenitors per cell basis unchanged frequencies blast cells BM unchanged Mean levels PB CFU-GM day CFU-GEMM baseline values days initial levels end treatment Peripheral blood BFU-E majority patients normal marrow days augmentation BFU-E CFU-GEMM patients MDS PB BFU-E CFU-GEMM Total leukocyte neutrophil eosinophil counts patients peak response median days small increase reticulocytes elevation hemoglobin hematocrit platelet counts patients preserved marrow function induces multilineage response vivo proliferation multipotential lineage-restricted progenitors due effects progenitor cells